Contact UsQuotation
Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Proceed to checkoutContinue shopping
TOPBioactivityChemical infoStorage&SolubilityCalculator

Cyclin A/B RxL-IN-1

Catalog No. T213106 Copy Product Info
🥰Excellent
Cyclin A/B RxL-IN-1 is an inhibitor targeting the interaction between Cyclin A/B RxL and the hydrophobic patch (HP). It exhibits an IC50 of 0.12 μM for inhibiting Cyclin A. In xenograft models derived from murine cell lines (CDX), Cyclin A/B RxL-IN-1 demonstrates antitumor efficacy. CDK-IN-19 is applicable for research on E2F-driven cancers, including small cell lung cancer (SCLC).

Cyclin A/B RxL-IN-1

Copy Product Info
🥰Excellent
Catalog No. T213106

Cyclin A/B RxL-IN-1 is an inhibitor targeting the interaction between Cyclin A/B RxL and the hydrophobic patch (HP). It exhibits an IC50 of 0.12 μM for inhibiting Cyclin A. In xenograft models derived from murine cell lines (CDX), Cyclin A/B RxL-IN-1 demonstrates antitumor efficacy. CDK-IN-19 is applicable for research on E2F-driven cancers, including small cell lung cancer (SCLC).

Cyclin A/B RxL-IN-1
Cas No. 3036231-62-3
Pack SizePriceUSA StockGlobal StockQuantity
10 mgInquiryInquiryInquiry
50 mgInquiryInquiryInquiry
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
Cyclin A/B RxL-IN-1 is an inhibitor targeting the interaction between Cyclin A/B RxL and the hydrophobic patch (HP). It exhibits an IC50 of 0.12 μM for inhibiting Cyclin A. In xenograft models derived from murine cell lines (CDX), Cyclin A/B RxL-IN-1 demonstrates antitumor efficacy. CDK-IN-19 is applicable for research on E2F-driven cancers, including small cell lung cancer (SCLC).
In vitro
Cyclin A/B RxL-IN-1 (Compound 34) is a compound that suppresses the proliferation of small cell lung cancer (SCLC) cells disrupted by RB1/E2F dysfunction, with GI50 values of 0.016 μM in NCI-H69 cells and 0.048 μM in NCI-H1048 cells. It selectively binds to Cyclin A/B, exhibiting a Cyclin A FP2 IC50 of 0.079 μM, compared to a Cyclin E FP2 IC50 of 0.958 μM.
In vivo
Cyclin A/B RxL-IN-1 (Compound 34), administered intraperitoneally at doses of 50-100 mg/kg once daily for 14 consecutive days, induces tumor growth inhibition in the NCI-H1048 SCLC xenograft model. At a dose of 100 mg/kg, delivered intraperitoneally once daily for 18 consecutive days, it demonstrates significant antitumor activity in the NCI-H69 SCLC xenograft model.
Chemical Properties
Molecular Weight972.95
FormulaC46H63Cl2F4N7O7
Cas No.3036231-62-3
SmilesC(=O)(C1(C(F)(F)F)CC2(C1)CCC2)N3[C@H](C(N[C@H](C(N(C)[C@@H]4C(=O)N[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC5=C(Cl)C=CC(Cl)=C5)C(=O)NC(C)(C)C(=O)NCCCC4)=O)[C@H]6CC6)=O)C[C@@H](F)C3
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Citations

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy Cyclin A/B RxL-IN-1 | purchase Cyclin A/B RxL-IN-1 | Cyclin A/B RxL-IN-1 cost | order Cyclin A/B RxL-IN-1 | Cyclin A/B RxL-IN-1 in vivo | Cyclin A/B RxL-IN-1 in vitro | Cyclin A/B RxL-IN-1 formula | Cyclin A/B RxL-IN-1 molecular weight
TargetMol | Logo

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.